Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telaprevir in genotype 2 hepatitis C non-responders
NCT01468584Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Nov 2011
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of telaprevir in hepatitis C (HCV), sponsored by Mitsubishi Tanabe Pharma. Primary endpoint: Sustained Viral Response. Started Nov 2011; status: completed.
02
Drugs
telaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01468584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01468584.